Bisacodyl
Colon Cancer
Long Neck Medical EnterprisesSmall moleculeDormant
D
28/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 65/ 100
Competitive context
128 Active assets in the Colon Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Sun Yat-sen University | Phase 3 | BB |
Calcium folinate pentahydrate Akeso | Phase 3 | BB |
MACROGOLS University Medical Center Ho Chi Minh City (UMC) | Phase 4 | BB |
PANITUMUMAB IFOM ETS - The AIRC Institute of Molecular Oncology | Phase 3 | B |
Cetuximab Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 3 | B |
View all 50 →
Same molecule, other indications
Bisacodyl is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →